Skip to Main Content

One of the discrete institutional innovations of Dr. Snyderman’s tenure as Chancellor was the creation of the Duke Clinical Research Institute (DCRI). Looked down upon by top-tier medical schools and academic medical centers, clinical research and trials nevertheless seemed to Dr. Snyderman an inherently important function of academic medicine and one bound to grow in importance and prestige. This prediction proved true as Duke became the leader in academic clinical research and garnered multiple NIH and commercial grants. The DCRI grew in importance and prestige with the new appreciation of translational research. Other institutions followed Duke’s lead.

You do not currently have access to this chapter.
Don't already have an account? Register
Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal